Pfizer cans PF-08046045, but keeps PF-08046044 for now.
ApexOnco Front Page
Recent articles
The Fortitude-102 trial, testing a bemarituzumab/Opdivo/chemo triplet, has failed.
Skyscraper-07 fails, while a Poseida-originated Car-T is also scrapped.
The curtain lifts on Veritac-2, rusfertide, and another double plenary for Astra.
The PD-1 x VEGF molecule's latest win comes from Akeso's Harmoni-6 trial.
Meanwhile, the company plays down the risk of Jaypirca’s CLL approval being rescinded.
Gilead’s TROP2 ADC prevails in Ascent-04, in first-line PD-L1-positive TNBC.
The first global pivotal trial will be in first-line triple-negative breast cancer.
